TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26387810

Group type: EXPERIMENTAL
Intervention: HDF (hemodiafiltration)
Number of subjects: 36

Group type: COMPARATOR
Intervention: BHD (bicarbonate dialysis)
Number of subjects: 36
Study: 26388950

Group type: EXPERIMENTAL
Intervention: Quality enhancement programmes in public primary care
Number of subjects: 127977
Study: 26389799

Group type: EXPERIMENTAL
Intervention: Benzimidazoles treatment (abrogated after normalization of FDG-PET/CT and anti-EmII/3-10 levels)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (group B with continued chemotherapy)
Number of subjects: 34
Study: 26389849

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab (80, 160, or 320 mg every 2 weeks × 4 doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab (160 or 320 mg twice-weekly × 16 doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab
Number of subjects: 21
Study: 26390038

Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (humanized anti-CD47 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (humanized anti-CD47 antibody) + rituximab
Number of subjects: 0
Study: 26390837

Group type: EXPERIMENTAL
Intervention: COVA322 (bispecific TNF/IL-17A inhibitor)
Number of subjects: 0
Study: 26391016

Group type: EXPERIMENTAL
Intervention: LVIS device
Number of subjects: 31
Study: 26391354

Group type: EXPERIMENTAL
Intervention: Children with at least one sensitive TAS2R38 allele (AP or PP genotype)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Children's reports of past problems with medication
Number of subjects: 172
Study: 26391458

Group type: EXPERIMENTAL
Intervention: Zenith Alpha thoracic endovascular graft
Number of subjects: 50
Study: 26391648

Group type: EXPERIMENTAL
Intervention: Participants with RCTs
Number of subjects: 20
Study: 26391665

Group type: EXPERIMENTAL
Intervention: AV300 vein viewer
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard peripheral IV cannulation without supporting device (control group)
Number of subjects: 238
Study: 26392035

Group type: EXPERIMENTAL
Intervention: High-frequency, low-magnitude vibration signal (approximately 33Hz and 0.3g)
Number of subjects: 28
Study: 26392057

Group type: EXPERIMENTAL
Intervention: Childhood pneumonia
Number of subjects: 10192

Group type: EXPERIMENTAL
Intervention: Childhood pneumonia with asthma
Number of subjects: 10192
Study: 26392102

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 43
Study: 26392348

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a therapy for nine days
Number of subjects: 50
Study: 26392763

Group type: EXPERIMENTAL
Intervention: Daily physical activity level (PAL) measured by activity monitor (SenseWear Pro™)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher PAL
Number of subjects: 123
Study: 26392838

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26393854

Group type: EXPERIMENTAL
Intervention: Radiation with Androgen Deprivation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation without Androgen Deprivation Therapy
Number of subjects: 0
Study: 26394198

Group type: EXPERIMENTAL
Intervention: A2NTX (low-molecular weight subtype A2 preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: onabotulinumtoxinA (A1LL)
Number of subjects: 0
Study: 26394202

Group type: EXPERIMENTAL
Intervention: Riluzole (8 mg/kg) administered 1 hour after injury and every 12 hours thereafter for 7 days at 6 mg/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vehicle solution (control group)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham injured rats (C2 laminectomy without hemisection)
Number of subjects: 3
Study: 26394823

Group type: EXPERIMENTAL
Intervention: Children with MLBW at 3.5 years
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Children with MLBW at 7 years
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Children with MLBW
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 285
Study: 26395347

Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg once every 3 weeks) + Nintedanib (200 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Volasertib + Nintedanib
Number of subjects: 30
Study: 26395501

Group type: EXPERIMENTAL
Intervention: Anti-CCP positive individuals
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Anti-CCP negative individuals
Number of subjects: 2028
Study: 26396053

Group type: EXPERIMENTAL
Intervention: High-dosed intravenous methylprednisolone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune prophylaxis with beta-interferon or glatiramer acetate
Number of subjects: 0
Study: 26396157

Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day)
Number of subjects: 44
Study: 26396720

Group type: EXPERIMENTAL
Intervention: Soy isoflavones capsules
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 26398152

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Osteoporosis (OP)
Number of subjects: 1825

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1825
Study: 26398290

Group type: EXPERIMENTAL
Intervention: Fasting triglycerides
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Post-challenge triglycerides
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Oral fat challenge
Number of subjects: 158
Study: 26398503

Group type: EXPERIMENTAL
Intervention: Telaprevir plus pegylated interferon-α and ribavirin (PR) for 12 weeks followed by PR alone.
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Higher baseline FibroScan values.
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Higher FibroScan values.
Number of subjects: 1772
Study: 26400226

Group type: EXPERIMENTAL
Intervention: Thermistor-based tympanic temperature (T tymp) measurement after exposure to cooling conditions.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thermistor-based tympanic temperature (T tymp) measurement after 10 min of cooling exposure.
Number of subjects: 13
Study: 26400297

Group type: EXPERIMENTAL
Intervention: MSCs/HGF (autologous bone marrow MSCs transfected with human HGF cDNA) administered intravenously at a dose of 2 x 10(6) cells/kg, weekly for three consecutive weeks.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: MSCs/HGF
Number of subjects: 4
Study: 26400368

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 26400417

Group type: EXPERIMENTAL
Intervention: HVSP (volitional hyperventilation at spontaneous breathing rate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HV20 (volitional hyperventilation at 20/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SP1 (spontaneous breathing protocol 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SP2 (spontaneous breathing protocol 2)
Number of subjects: 18
Study: 26401247

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 15
Study: 26401256

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 11
Study: 26402159

Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Aging
Number of subjects: 58
Study: 26402736

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy with a custom-made, titratrable mandibular advancement device (OAm)
Number of subjects: 51
Study: 26403509

Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg) plus pemetrexed (500 mg/m2) and carboplatin (5-6 AUC) every 21 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LY2090314 monotherapy (≥ 40 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg) plus pemetrexed/carboplatin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg)
Number of subjects: 41
Study: 26404501

Group type: EXPERIMENTAL
Intervention: Self-reported fatigue severity
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: High-risk IPSS score
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Fatigue assessment in multivariate models
Number of subjects: 280
Study: 26404729

Group type: EXPERIMENTAL
Intervention: Modified uvulopalatopharyngoplasty (UPPP) surgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study: 26405287

Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 282

Group type: COMPARATOR
Intervention: Mild/moderate asthma
Number of subjects: 282
Study: 26405521

Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Central venous catheter
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in elective surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in urgent surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in emergency surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Central venous catheter in elective surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Central venous catheter in urgent surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Central venous catheter in emergency surgery
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Arterial waveform analysis
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler ultrasound
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Other technologies
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Variation in cardiac output monitoring use across nations
Number of subjects: 12170

Group type: EXPERIMENTAL
Intervention: Variation in central venous catheter use across nations
Number of subjects: 12170
Study: 26405576

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with L19-IL2
Number of subjects: 0
Study: 26405584

Group type: EXPERIMENTAL
Intervention: DPX-Survivac vaccine in combination with metronomic cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DPX-Survivac vaccine
Number of subjects: 0
Study: 26405686

Group type: EXPERIMENTAL
Intervention: Diazoxide (0.3 mg/d)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diazoxide (4 mg/d)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diazoxide (0.3 mg/d) and (4 mg/d)
Number of subjects: 102
Study: 26407163

Group type: EXPERIMENTAL
Intervention: Severe CAP
Number of subjects: 430

Group type: COMPARATOR
Intervention: Non-severe CAP
Number of subjects: 430
Study: 26407235

Group type: EXPERIMENTAL
Intervention: PF-03084014 (gamma-secretase inhibitor)
Number of subjects: 0
Study: 26407255

Group type: EXPERIMENTAL
Intervention: IPV-OPV-OPV (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPV-IPV-OPV (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OPV-OPV-OPV (Group C)
Number of subjects: 0
Study: 26407818

Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI) 10 mg/kg plus Dacarbazine (DTIC) 850 mg/m(2) every 3 weeks for four doses (q3w × 4)
Number of subjects: 15
Study: 26408329

Group type: EXPERIMENTAL
Intervention: Acoustic gastrointestinal surveillance (AGIS) biosensor; applied for 60 min before and continuously after abdominal surgery.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AGIS biosensor; used to predict POI onset.
Number of subjects: 28
Study: 26409297

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50
Study: 26409610

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 211
Study: 26409628

Group type: EXPERIMENTAL
Intervention: Framingham coronary heart disease risk score Q4
Number of subjects: 3061

Group type: EXPERIMENTAL
Intervention: Framingham cardiovascular risk score Q4
Number of subjects: 3061

Group type: EXPERIMENTAL
Intervention: Framingham stroke risk profile Q4
Number of subjects: 3061

Group type: EXPERIMENTAL
Intervention: Continuous-scale Framingham risk scores
Number of subjects: 3061
Study: 26409812

Group type: EXPERIMENTAL
Intervention: Immunization of pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant administration of recommended vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of women in high-risk settings in trials
Number of subjects: 0
Study: 26409873

Group type: EXPERIMENTAL
Intervention: Composite Stressor scores, perceived stress, or depression scores
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Individual stressors
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 606
Study: 26410176

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose combined oral contraceptive (1.0-mg norethindrone acetate and 10-mcg ethinyl estradiol)
Number of subjects: 1581
Study: 26410424

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg every 3 weeks for four doses
Number of subjects: 20
Study: 26410619

Group type: EXPERIMENTAL
Intervention: Eight drugs targeting 18 molecular cohorts, specific drugs not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nextera next-generation sequencing platform designed by Illumina.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-clinical justification for biomarker-drug combinations, molecular exclusion rules, and trumping strategy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep genomic analysis of pre- and post-treatment biopsies, patient-derived xenograft models, longitudinal ctDNA collection.
Number of subjects: 0
Study: 26411993

Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels 9.1-10%
Number of subjects: 6313

Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels >10%
Number of subjects: 6313

Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels 8.1-9%
Number of subjects: 6313

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients
Number of subjects: 6313
Study: 26412290

Group type: EXPERIMENTAL
Intervention: Twelve-week resistance exercise program (3 times/week; 3 sets, 6-8 repetitions at 75-80% of the 1-repetition maximum)
Number of subjects: 235
Study: 26413873

Group type: EXPERIMENTAL
Intervention: Low-dose IL2 (1x10^6 U/m2 first month, 1.5x10^6 U/m2 following months)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Low-dose IL2
Number of subjects: 5
Study: 26413903

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) use
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Age >37 years
Number of subjects: 673

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 673
Study: 26413982

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m² on day 1 and prednisone 100 mg/day on days 1-5 of each cycle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-prednisone chemotherapy
Number of subjects: 38
Study: 26415085

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to maternal cancer with treatment (chemotherapy, radiotherapy, surgery, or other drug treatments)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no cancer diagnosis)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to maternal cancer with or without treatment
Number of subjects: 129
Study: 26415600

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with routine platelet reactivity testing
Number of subjects: 8582

Group type: COMPARATOR
Intervention: Early generation DES
Number of subjects: 8582

Group type: COMPARATOR
Intervention: No procedural intravascular ultrasound guidance
Number of subjects: 8582

Group type: COMPARATOR
Intervention: Premature discontinuation of dual antiplatelet therapy
Number of subjects: 8582

Group type: COMPARATOR
Intervention: High platelet reactivity on clopidogrel
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Presence of 0 to 3 modifiable risk factors
Number of subjects: 8582
Study: 26415764

Group type: EXPERIMENTAL
Intervention: Breastmilk intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (GDM children)
Number of subjects: 0
Study: 26415945

Group type: EXPERIMENTAL
Intervention: Patients with spasticity
Number of subjects: 328

Group type: COMPARATOR
Intervention: Patients without spasticity
Number of subjects: 328
Study: 26415998

Group type: EXPERIMENTAL
Intervention: Tinnitus Functional Index (TFI)
Number of subjects: 294
Study: 26416092

Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) in eyes with IRD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) in normal eyes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interobserver agreement in normal eyes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in eyes with IRD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cone spacing measures correlation between visits for both groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cone spacing measures from fellow eyes of the same subject
Number of subjects: 30
Study: 26416471

Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Telaprevir
Number of subjects: 118
Study: 26416513

Group type: EXPERIMENTAL
Intervention: PNH/SAA subgroup
Number of subjects: 282

Group type: COMPARATOR
Intervention: Classic PNH subgroup
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Both subgroups
Number of subjects: 282
Study: 26416564

Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m² bid, Paclitaxel 60 mg/m²/week, Carboplatin AUC of 6
Number of subjects: 54
Study: 26416574

Group type: EXPERIMENTAL
Intervention: Care Pathway for Primary Palliative Care (CPPPC) implemented by general practitioners (GPs).
Number of subjects: 5

Group type: COMPARATOR
Intervention: Patient populations of participating GPs.
Number of subjects: 5
Study: 26416780

Group type: EXPERIMENTAL
Intervention: Prolonged-infusion meropenem (40 mg/kg every 8 h as a 3 h infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prolonged-infusion meropenem
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5 h infusion
Number of subjects: 30
Study: 26416813

Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet (MD)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Vegetable-based diets
Number of subjects: 153

Group type: COMPARATOR
Intervention: Omnivore diet
Number of subjects: 153
Study: 26416896

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT)
Number of subjects: 47
Study: 26416897

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 476

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 476
Study: 26417268

Group type: EXPERIMENTAL
Intervention: Energy-restricted dietary weight-loss intervention for six months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary vitamin C
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary tocopherols
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary lycopene
Number of subjects: 47
Study: 26417987

Group type: EXPERIMENTAL
Intervention: Biomodulatory metronomic therapy
Number of subjects: 0
Study: 26418126

Group type: COMPARATOR
Intervention: No EEG suppression
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: EEG suppression (divided into quartiles based on duration)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: EEG suppression (per 1-minute increase)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: EEG suppression
Number of subjects: 727
Study: 26418191

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (140 μg/kg/min) infusion for 1-2 min
Number of subjects: 648
Study: 26418430

Group type: EXPERIMENTAL
Intervention: New method for removing thermosensitive acrylic punctal plugs (involves local anesthesia, lid clamp, and microforceps if necessary)
Number of subjects: 14
Study: 26418443

Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging in MacTel 2 patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normative database
Number of subjects: 8
Study: 26419191

Group type: EXPERIMENTAL
Intervention: Cadazolid 3000 mg oral dose
Number of subjects: 6
Study: 26419198

Group type: EXPERIMENTAL
Intervention: EV71 inactivated vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 26420017

Group type: EXPERIMENTAL
Intervention: Sedation or analgesia (continuous infusion, intermittent doses, or both)
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockers
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: O-SH-GA (opioids, sedatives-hypnotics, general anaesthetics)
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Pain assessments
Number of subjects: 6680
Study: 26420235

Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg orally once daily plus erlotinib 150 mg orally once daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Navitoclax and erlotinib combination
Number of subjects: 11
Study: 26420684

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 302

Group type: COMPARATOR
Intervention: MTX + anti-TNF
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX, sulfasalazine, hydroxychloroquine)
Number of subjects: 302

Group type: COMPARATOR
Intervention: anti-TNF
Number of subjects: 302
Study: 26420854

Group type: EXPERIMENTAL
Intervention: Cervicovaginal vaccination with TA-HPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of TA-HPV
Number of subjects: 0
Study: 26420969

Group type: EXPERIMENTAL
Intervention: Early endoscopic ultrasonography (EUS) performed within 48 hours of admission; mean procedure time 14.7 min (range 9-34 min)
Number of subjects: 71